Insider · CIK 0001857479
Paul Rivard
Files at QCLS (MyMD Pharmaceuticals, Inc.). First filing Dec 8, 2022, latest Dec 8, 2022.
In brief
Paul Rivard files SEC Form 4 as officer at QCLS (MyMD Pharmaceuticals, Inc.). Since Dec 8, 2022, Paul Rivard has reported 1 open-market buy worth $15k and 0 open-market sells worth $0, the latest filed on Dec 8, 2022.
A track record needs three past buys with six months of prices behind them; Paul Rivard has 0, so none is measured yet.
The newest scored trade: bought $15k of QCLS on Dec 8, 2022, filed Dec 8, 2022, scored 33 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
QCLS: MyMD Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | QCLSbuy MyMD Pharmaceuticals, Inc. | $15k 10,000 shares | +5% | +7% from low-78% from high |
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 8, 2022 | QCLS MyMD Pharmaceuticals, Inc. | POpen-market purchase Common stock | +10,000 | $1.53 | $15k | 225,000 | Dec 8, 2022 |
Questions about Paul Rivard
Answered from the filings on this page, as of the latest one.
Is Paul Rivard buying or selling?
Not in the last 12 months. Paul Rivard's latest open-market trade on SEC Form 4 was bought $15k of QCLS on Dec 8, 2022.
How did Paul Rivard's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Paul Rivard has 0.
Where does Paul Rivard file Form 4?
Paul Rivard has filed Form 4 at QCLS (MyMD Pharmaceuticals, Inc.) as EVP of Operations, GC. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.